-- 米国財務省は月曜日、第2四半期の借入額を1,890億ドルと見込んでいると発表した。これは前回発表した1,090億ドルを上回る額である。 借入額の増額の理由は、純キャッシュフローの予測が下方修正されたことによるもので、四半期初めの現金残高が予想を上回ったことで一部相殺された。財務省は、四半期末の現金残高を9,000億ドルと引き続き想定している。 第3四半期の借入額は6,710億ドルと見込まれ、9月末の現金残高は9,500億ドルと推定されている。 財務省は第1四半期に5,770億ドルを借り入れ、3月末の現金残高は8,930億ドルだった。財務省は以前、借入額を5,740億ドル、3月末の現金残高を8,500億ドルと見込んでいた。 財務省によると、第1四半期の借入額が若干増加したのは、想定よりも高い四半期末の現金残高が原因だったが、純現金流入の増加によって部分的に相殺されたという。
Related Articles
Mining & Metals
PJX Resources Adopting Semi-Annual Financial Reporting
$PJX.V
Australia
Lattice Semiconductor to Acquire AMI for $1.65 Billion in Cash and Stock From THL Partners
Lattice Semiconductor (LSCC) agreed to acquire AMI, a cloud and AI-server management software company, for $1.65 billion in cash and stock from THL Partners.The purchase includes $1 billion in cash and $650 million in Lattice stock. The acquisition is expected to close in Q3, subject to regulatory approvals and other conditions, Lattice said Monday in a statement.The transaction is expected to be accretive to gross margin, free cash flow and earnings per share on an adjusted basis, and AMI is projected to generate more than $200 million in revenue in 2026, Lattice said.Lattice shares rose 0.4% in after-hours trading after gaining 3.8% in the regular session.
$LSCC
Research
Research Alert: Vertex Reports Mixed Q1, Reaffirms Full-year 2026 Financial Guidance
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Vertex delivered mixed Q1 results with revenue of $2.99B (+8% Y/Y) falling $10M short of expectations, though non-GAAP EPS of $4.47 (+10% Y/Y) beat the consensus by $0.16. The quarter demonstrated successful execution of VRTX's multi-product launch strategy, with ALYFTREK generating $424.4M (vs. $53.9M prior year), CASGEVY contributing $42.9M (+202% Y/Y), and JOURNAVX adding $29.0M in its second commercialization year. Recent FDA label extensions for ALYFTREK and TRIKAFTA expanded CF patient eligibility to ~95% in the U.S., adding roughly 800 more patients. VRTX maintained its 2026 guidance unchanged with total revenue expectations of $12.95B-$13.1B and non-CF product revenue of $500M or greater. We view the operating leverage positively, with revenue growth outpacing expense increases, and believe the diversification strategy beyond CF continues to gain traction with meaningful contributions from newly launched therapies across multiple therapeutic areas.
$VRTX